ライフサイエンスコーパス: total bilirubin

1 nine transaminase, alkaline phosphatase, and total bilirubin).

2 lar with regard to age, prothrombin time and total bilirubin.

3 serum creatinine, and (5) preoperative serum total bilirubin.

4 nces between groups were seen with Pi-GST or total bilirubin.

5 ved by day 14 with no accompanying change in total bilirubin.

6 icant (P < 0.05) decrease was only noted for total bilirubin.

7 s a safe and efficacious method for reducing total bilirubin.

8 LP), gamma-glutamyl transpeptidase (GGT), or total bilirubin.

9 ne aminotransferase elevation plus increased total bilirubin.

10 d biochemical cholestasis by day of life 15 (total bilirubin 0.2 vs. 2.9 mg/dL, P = 0.01).

11 5.2 vs 861.8 +/- 813.7 U/L; p </= 0.01), and total bilirubin (0.13 +/- 0.05 vs 0.30 +/- 0.14 mg/dL; p

12 activity (897 +/- 84 vs. 876 +/- 95, P =.5), total bilirubin (0.9 +/- 0.1 vs. 1 +/- 0.1, P =.07), asp

13 jaundice (alanine transaminase 2474 IU/L and total bilirubin 141 umol/L with mild coagulopathy).

14 d ratio [1.2, P < 0.001; 1.1, P = 0.001] and total bilirubin (2.7, P = 0.001; 2.1, P = 0.05)).

15 cant decline in albumin levels and increased total bilirubin; 3 experienced duodenal or colonic bleed

16 alized ratio (1.5 and 1.2, respectively) and total bilirubin (4.6 and 2.7) were significantly greater

17 concentration range of 100 to 500 umolL(-1) total bilirubin (4:1 ratio of unconjugated to conjugated

18 e 892 U/L, alkaline phosphatase 358 U/L, and total bilirubin 6.1 mg/dL.

19 ars), and they had elevated median values of total bilirubin (6.67 mg/dL), alanine aminotransferase (

20 ubin variation, was strongly associated with total bilirubin (a 0.68-SD increase in bilirubin levels

21 erase (AST), alkaline phosphatase (ALP), and total bilirubin across 312,671 White British participant

22 minotransferase (ALT), alkaline phosphatase, total bilirubin, albumin, creatinine, and hemoglobin; pr

23 or size, tumor capsule, pathological grades, total bilirubin, albumin, prothrombin time, alpha-fetopr

24 n dataset included 1,756 patients with serum total bilirubin, alkaline phosphatase, aspartate aminotr

25 minotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, gamma-glutamyl tr

26 e, plasma lipids or the lipoprotein profile, total bilirubin, alkaline phosphatase, serum aspartate a

27 he hepatic parameters ALP, GGT, ALT, AST and total bilirubin, also considering the adverse events.

28 gh WBC count, raised serum ALT, raised serum total bilirubin and a lack of endoscopy were independent

29 Mean serum total bilirubin and alanine aminotransferase level on se

30 POD3 of 7 total bilirubin and alanine aminotransferase; POD3 aspar

31 or more times the upper limit of normal with total bilirubin and alkaline phosphatase two or more tim

32 emained unchanged, a significant increase in total bilirubin and an upward trend in serum blood urea

33 Current median follow-up values for total bilirubin and aspartate aminotransferase levels in

34 cellent: current median follow-up values for total bilirubin and aspartate aminotransferase were 0.5

35 ratified into four groups according to serum total bilirubin and AST and were treated with escalating

36 (n = 66, 12%) had increased IL-6, ICAM, and total bilirubin and decreased platelets compared to phen

37 minotransferase, aspartate aminotransferase, total bilirubin and direct bilirubin levels as well as s

38 ak was located at chromosome 2q37.1 for both total bilirubin and direct bilirubin, with 29 SNPs reach

39 cantly lower percentage haemocrit and higher total bilirubin and free haemoglobin concentration (P <

40 her levels of serum alkaline phosphatase and total bilirubin and lower levels of total cholesterol an

41 um concentrations and an average increase of total bilirubin and phosphate concentration towards the

42 iated with hemolysis (lactate dehydrogenase, total bilirubin) and inflammation (tumor necrosis factor

43 95% CI, 1.03 to 1.08 per 1 mg/dl increase in total bilirubin) and metabolic acidosis (RR, 0.95; 95% C

44 biochemical (e.g., alkaline phosphatase, and total bilirubin), and clinical evaluation was combined w

45 erase, alanine aminotransferase, bile acids, total bilirubin), and increased KC expression of interle

46 e performed for percentage change in ALP and total bilirubin, and adverse events leading to treatment

47 [AST]/alanine aminotransferase [ALT] ratio, total bilirubin, and albumin) with three categories of c

48 tional normalized ratio of prothrombin time, total bilirubin, and creatinine).

49 Ventricular CSF levels of hemoglobin, iron, total bilirubin, and ferritin decreased between temporar

50 aminotransferase, alanine aminotransferase, total bilirubin, and gamma glutamyl transferase were hig

51 presented with higher alkaline phosphatase, total bilirubin, and GLOBE scores than White patients; a

52 2 or greater low albumin, grade 1 or greater total bilirubin, and grade 2 or greater anemia were asso

53 se severity based on serum creatinine, serum total bilirubin, and INR and has been shown to be useful

54 lower albumin, lower platelet count, higher total bilirubin, and more advanced Ishak fibrosis score

55 d decreased plasma alanine aminotransferase, total bilirubin, and serum alkaline phosphatase levels b

56 95% CI (1.9-63.0); p = 0.003], and elevated total bilirubin [aOR 16.1, 95% CI (3.2-80.8); p = 0.001]

57 ferase (GGT), alkaline phosphatase (ALP) and total bilirubin are also reported, although less frequen

58 ures of portal hypertension, platelet count, total bilirubin, aspartate aminotransferase (AST), album

59 th >40 mumol/L group had significantly lower total bilirubin, aspartate aminotransferase, alanine ami

60 Lower platelet count and higher total bilirubin at 2 years were significantly associated

61 ne variables lower platelet count and higher total bilirubin at 2 years were significantly associated

62 Median serum ALT and total bilirubin at presentation were 462 U/L (IQR 266-79

63 serum levels of alanine aminotransferase and total bilirubin at presentation were independent risk fa

64 t cirrhosis had significantly higher initial total bilirubin at the onset of histologic recurrence an

65 ntribute to variation among modern humans in total bilirubin, balding, hemoglobin levels, and lung ca

66 In a subgroup with total bilirubin between 2 and 6 mg/dL at 3 months after

67 s for an increase in alanine transaminase or total bilirubin between both CSL112 arms and placebo was

68 transferase (AST), Direct Bilirubin (BIL.D), Total Bilirubin (BIL.T)-and high-sensitivity C-reactive

69 Median total bilirubin, CA19-9, and carcinoembryonic antigen (C

70 Total bilirubin changes were similar across arms, and tr

71 n neurotoxicity than the conventionally used total bilirubin concentration (BT).

72 ne concentration of 132.60 umol/L or less, a total bilirubin concentration of 34.21 umol/L or less, a

73 OG performance status of 2 or less who had a total bilirubin concentration two-times the upper limit

74 o clear) were then utilized to calculate the total bilirubin concentration.

75 nitrogen, sodium, chloride, phosphorus, and total bilirubin concentrations and lower aspartate amino

76 in plasma samples from patients with similar total bilirubin concentrations but varying levels of con

77 Total bilirubin concentrations were stabilised, with sig

78 survival after adjustments for age, gender, total bilirubin, creatinine, prothrombin time, and diagn

79 Over the same interval total bilirubin declined by a median of 70 mumol/L (p <

80 Serum total bilirubin decreased after PEBD in FIC1 (8.1 +/- 4.

81 ides the capabilities to not only quantitate total bilirubin (Deming-regression slope of 0.95, R(2) =

82 Six patients with FIB-4 scores of > 3.25 had total bilirubin elevation > 3 x the upper normal limit (

83 ed in 4 patients, of which 1 had concomitant total bilirubin elevation.

84 ) patients, whereas alkaline phosphatase and total bilirubin elevations were rare.

85 patients in the deferred treatment group had total bilirubin elevations.

86 Total bilirubin for the above-normal group was 2.1+/-0.9

87 ard designed to measure the concentration of total bilirubin from several drops of blood at the point

88 tate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) a

89 Age, total bilirubin, gamma-glutamyl transferase, and alanine

90 mg/dL or less, compared to 36% in those with total bilirubin greater than 1.3 mg/dL.

91 acteristics: ascites, esophageal varices, or total bilirubin greater than 2 mg/dL.

92 ient survival than patients converted with a total bilirubin > 10 mg/dl (P=0.00002 and P=0.00125, res

93 elevations > 3 x upper limit of normal with total bilirubin > 2 x upper limit of normal were reporte

94 dehydrogenase > 500 international units and total bilirubin > 3.0 mg/dL or serum transaminase level

95 patients with recent surgery, malignancy, or total bilirubin > 34 micromol/L (> 2 mg/dl).

96 ze > or =8 mm on admission ultrasound, serum total bilirubin > or = 1.7 mg/dL, or serum amylase > or

97 CLIF-C ACLFs) and presence of liver failure (total bilirubin >/=12 mg/dL) at ACLF diagnosis.

98 the upper limit of normal or an increase in total bilirubin >2 times the upper limit of normal) or a

99 tio >1.5 or transaminases >5 times normal or total bilirubin >3 mg/dL; and needing mechanical ventila

100 ction (severe, mild-moderate vs. normal) and total bilirubin (>/= 2.0, 0.6 to <2.0 vs. <0.6 mg/dL).

101 Among HLT recipients, total bilirubin (hazard ratio [HR], 1.06; 95% confidence

102 transferase (HR 4.22, p 0.016), raised serum total bilirubin (HR 5.79, p 0.008) and lack of an endosc

103 eks after BDL significantly lowers the serum total bilirubin in both groups.

104 th sexes, alanine aminotransferase (ALT) and total bilirubin in men were inversely associated, while

105 lot clinical study using BiliSpec to measure total bilirubin in neonates at risk for jaundice at Quee

106 elevated levels of alanine transaminase and total bilirubin in patients receiving TACE plus RT compa

107 The mean serum total bilirubin in the adult population is 0.62 +/- 0.00

108 0%), and grade 1 or 2 elevation in levels of total bilirubin (in 12%), alkaline phosphatase (in 21%),

109 Compared with fresh RBCs, mean serum total bilirubin increased by 0.55 mg/dL at 4 hours after

110 Total bilirubin increased slightly after transplantation

111 y atresia patients were inversely related to total bilirubin, indicating that extrahepatic bile duct

112 elded 6 parameters of interest: age <1 year, total bilirubin, international normalized ratio (INR), a

113 endpoints were successful surgical drainage (total bilirubin less than 2 mg/dL within the first 3 mon

114 to adverse events, albumin level < 3.5 g/dL, total bilirubin level > 1.2 g/dL, advanced liver disease

115 Significant liver insufficiency (total bilirubin level > 10 mg/dL or international normal

116 aminotransferase level >1000 U/L (P = .027), total bilirubin level >7 mg/dL (P = .036), and IL28B.rs1

117 per liter; P<0.001 for both comparisons) and total bilirubin level (-0.02 and -0.05 mg per deciliter

118 (adjusted OR: 6.25 [2.31-16.92]; p < 0.001), total bilirubin level (adjusted OR: 3.01 [1.85-4.89]; p

119 as obtained which shows optimal criterion at Total Bilirubin Level 1.06 mg/dl where sensitivity was 9

120 cromol/L, alanine aminotransferase 4079 U/L, total bilirubin level 11.4 mg/dl, and glucose 70 mg/dl (

121 splant recipients with metastatic NETs whose total bilirubin level at transplantation was 1.3 mg/dL o

122 increased significantly with elevated serum total bilirubin level at transplantation.

123 The mean total bilirubin level for the responder group was 7.1 mg

124 ion risk factors for adverse outcomes in AC: total bilirubin level greater than 10 mg/dL and white bl

125 ll count greater than 20000 cells/microL and total bilirubin level greater than 10 mg/dL are independ

126 latelet count 100,000/microL or greater, and total bilirubin level less than 1.5 mg/dL.

127 Clinical success was defined as achieving total bilirubin level less than 1.8 mg/dL (30.8 mumol/L)

128 range, 65-195 U/L [1.1-3.3 mukat/L]), and a total bilirubin level of 1.5 mg/dL (25.7 umol/L) (normal

129 l range, 65-195 U/L [1.1-3.3 ukat/L]), and a total bilirubin level of 1.5 mg/dL (25.7 umol/L) (normal

130 he platelet count of 205 (x 10(9)/L) and the total bilirubin level of 1.7 mg/dL were the best cutoff

131 tive pattern on liver function tests, with a total bilirubin level of 3.5 mg/dL (59.9 umol/L) (normal

132 the percentage of participants with a serum total bilirubin level of less than 1.5 mg/dL with his/he

133 ds ratio, 3.4; 95% CI, 1.2-9.5; P = .02) and total bilirubin level of more than 10 mg/dL (odds ratio,

134 c insufficiency was peak postoperative serum total bilirubin level of more than 7 mg/dL or, in jaundi

135 The mean serum total bilirubin level of the study patients was 2.28 mg/

136 to study a potential causal effect of serum total bilirubin level on T2D risk.

137 Total bilirubin level was elevated by 2-fold in the Slco

138 tide decile, glomerular filtration rate, and total bilirubin level were included in a simplified mode

139 nine level at transplant, functional status, total bilirubin level, and donor age.

140 the plasma PfHRP2 level, parasitemia level, total bilirubin level, and RCD at a shear stress of 1.7

141 le appendicitis 09 subjects (12%) had raised total bilirubin level, while the remaining 66 subjects (

142 of at least 15% from baseline, and a normal total bilirubin level.

143 undice was diagnosed in patients with plasma total bilirubin levels >3 mg/dL.

144 Pretreatment total bilirubin levels (mean +/- standard deviation) wer

145 UGT1A1 genotype and total bilirubin levels are strongly associated with seve

146 Total bilirubin levels at admission (4.7 mg/dL vs 2.2 mg

147 ped cholestasis with significantly increased total bilirubin levels at day 7 (16 +/- 5.2 mg% vs. 3.7

148 1 U/L), but similar alkaline phosphatase and total bilirubin levels compared with HCV-negative patien

149 sus 12.9 in the control group, p-value 0.01. Total bilirubin levels decreased by 75% in the BCAA grou

150 otransferase, aspartate aminotransferase and total bilirubin levels demonstrated significant correlat

151 Serum total bilirubin levels in healthy patients reflect genet

152 surements showed a pooled mean difference in total bilirubin levels of -14 mumol/L, with pooled 95% C

153 rovement Network) with measurements of serum total bilirubin levels recorded 3 months before the firs

154 to tacrolimus before development of elevated total bilirubin levels showed a significant impact on lo

155 gh IAM was associated with higher peak serum total bilirubin levels than low IAM (median peak 21.7 ve

156 es from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from

157 In ATP11C-deficient mice, plasma total bilirubin levels were 6-fold increased, compared t

158 reduction of >=15% from baseline, and normal total bilirubin levels) at week 52.

159 High serum aminotransferases, total bilirubin levels, and leukopenia at study entry pr

160 ate aminotransferase, alkaline phosphatase), total bilirubin levels, sex, HCV viral loads, sodium lev

161 se, serum glutamic pyruvic transaminase, and total bilirubin levels, was significantly lower in the e

162 appendicitis 32 subjects (91.42%) had raised total bilirubin levels, while the remaining 03 (8.58%) h

163 ) 99mTc-mebrofenin adjusted to the patients' total bilirubin levels.

164 ferase >500 IU/L), alkaline phosphatase, and total bilirubin levels.

165 raging and may be related to the increase in total bilirubin levels.

166 icant (P < 0.05) decreases in AST, ALP, ALT, Total bilirubin, LPO, plasma glucose and significant (P

167 LT), or aspartate aminotransferase (AST); or total bilirubin < 0.6 xULN) were associated with a signi

168 nder, baseline albumin >/=3.5 g/dL, baseline total bilirubin </=1.2 mg/dL, absence of cirrhosis, and

169 ase (ALP) > 1.67 x upper limit of normal and total bilirubin <= 2 mg/dL at baseline.

170 R12 were higher albumin (>/=3.5 g/dL), lower total bilirubin (</=1.2 g/dL), absence of cirrhosis, and

171 ed with BNP (B-type natriuretic peptide) and total bilirubin, markers of chronic cardiac and hepatic

172 Serum total bilirubin may serve as a predictor of poor posttra

173 (MD - 55.69, 95% CI - 76.26 to - 35.13) and total bilirubin (MD - 0.08, 95% CI - 0.14 to - 0.03) wer

174 zard ratio, 0.46; P<0.0001) and preoperative total bilirubin (mg/dL; hazard ratio, 1.26; P=0.0002) we

175 Creatinine, total bilirubin, minority ethnicity, graft under-sizing,

176 sferase greater than three times the ULN and total bilirubin more than twice the ULN) after treatment

177 Patients with a total bilirubin of < or = 10 mg/dl at the time of conver

178 At baseline, the cases had a total bilirubin of 2.2 mg/dL, alanine aminotransferase o

179 Average total bilirubin on postoperative day 5 was 4.9 mg/dl.

180 rved with omaveloxolone without increases in total bilirubin or other signs of liver injury.

181 P < 0.01), ammonia (OR, 2.37; P < 0.01), and total bilirubin (OR, 2.25; P < 0.001).

182 y abnormalities in alanine aminotransferase, total bilirubin, or hemoglobin were observed.

183 n posttransplant alanine aminotransferase or total bilirubin, or the risk of intraoperative death and

184 portional hazards analysis was conducted and total bilirubin (P < 0.001, hazard ratio [HR] = 2.09, 95

185 ase (p = .009), creatinine kinase (p = .01), total bilirubin (p = .05), and plasma concentrations of

186 e attenuated after additional adjustment for total bilirubin (P = 0.08 and 0.02), which increased fro

187 6 x 10(-10) ), ALP (P = 9.5 x 10(-30) ), and total bilirubin (P = 2.9 x 10(-12) ).

188 ut transitory improvement in serum levels of total bilirubin (P =.001) and a significant, but margina

189 .03), foam cell clusters (P<0.01) and higher total bilirubin (P<0.02) and aspartate aminotransferase

190 iochemically, aspartate aminotransferase and total bilirubin, platelets, prothrombin time, sex, and a

191 rval [CI], 2.97, 20.43; P = 0.009), elevated total bilirubin (pooled MD, 0.14 mg/dL; 95% CI, 0.06, 0.

192 posttransplant alanine aminotransferase and total bilirubin, primary nonfunction, and 30-day and 1-y

193 ransplant outcomes, including reduced TIMP1, total bilirubin, proinflammatory MCP1, CXCL10 cytokines,

194 e above variables, in addition to donor age, total bilirubin, prothrombin time (PT), retransplantatio

195 the onset of histologic recurrence and peak total bilirubin (pT.Bili, the highest value in the ensui

196 crofluidic level for the ultimate purpose of total bilirubin quantitation.

197 IBD duration, PSC duration, and total bilirubin remained significant (p < 0.05) with mul

198 as normalization of alkaline phosphatase and total bilirubin revealed similar findings.

199 Prothrombin time (PT), total bilirubin, serum ammonia, and hepatic encephalopat

200 Total bilirubin (T-Bil) is an important clinical diagnos

201 Total bilirubin (TB) and direct bilirubin (dB), hematocr

202 Total bilirubin (TB) and serum bile acids (SBA) were hig

203 )Ugt1(-/-) mice expressed elevated levels of total bilirubin (TB) compared with Tg(UGT1(A1*1))Ugt1(-/

204 An alkaline phosphatase (AP) to total bilirubin (TB) ratio <4 yielded a sensitivity of 9

205 ansferase (ALT), alkaline phosphatase (AST), total bilirubin (TBIL) and direct bilirubin (DBIL) with

206 t (PSG) was decreased to normal level, while total bilirubin (TBIL) and liver function were significa

207 ) (MD - 21.80; 95% CI - 33.80 to - 9.80) and total bilirubin (Tbil) compared with placebo (MD - 0.51;

208 ansferase [ALT], alkaline phosphatase [ALP], total bilirubin [TBIL], and albumin) at three time point

209 nd KO mice; there was no difference in serum total bilirubin (TBili) levels.

210 levels of alanine aminotransferase (ALT) and total bilirubin (TBL).

211 enotype had a statistically greater baseline total bilirubin than patients with 6/6 or 6/7 genotype (

212 ion analysis demonstrated that pretransplant total bilirubin, UNOS status, and graft type significant

213 of 0.97 (R(2) = 0.960) when compared to the total bilirubin values determined in the clinical labora

214 The total bilirubin was 16.5 (11.2) umol/L, Alkaline Phospha

215 en tested in univariate models, pretreatment total bilirubin was able to modify the existing associat

216 Total bilirubin was elevated abnormally in 56 of 111 pat

217 ompared with twice-daily HDAC given when the total bilirubin was less than 2.0 mg/dL (33% v 14%; P =

218 splant values for recipient age, weight, and total bilirubin were 1.4 years, 12.3 kg, and 13.8 mg/dL,

219 Peak and discharge total bilirubin were 8.1+/-0.9 and 2.5+/-0.5 mg/dl.

220 e to viral infection levels of ALT, ALP, and total bilirubin were also determined.

221 Age, AST, AST/ALT ratio, and total bilirubin were identified as significant predictor

222 Increases in total bilirubin were more frequently observed in patient

223 median levels of prothrombin time, INR, and total bilirubin were, respectively, 33% (Q1-Q3, 21-41),

224 nts were not significantly different, except total bilirubin, which was lower in the FK arm (P=0.02).

225 (AST), gamma-glutamyltransferase (GGT), and total bilirubin, which-in combination-attenuated the reg

226 eemed to distinguish different phenotypes of total bilirubin within the TA indel genotypes.